Breaking Finance News

H.C. Wainwright issued a report on Tesaro (NASDAQ:TSRO), bumping its target to $158.00 earlier today

H.C. Wainwright increased the price target of Tesaro (NASDAQ:TSRO) to $158.00 reporting a potential upside of 0.34%.

Previously on Thursday August 17, 2017, Evercore ISI reported on Tesaro (NASDAQ:TSRO) increased the target price from $0.00 to $121.00. At the time, this indicated a possible upside of 0.07%.

Yesterday Tesaro (NASDAQ:TSRO) traded -0.26% lower at $117.91. The company’s 50-day moving average is $122.26 and its 200-day moving average is $134.38. The last closing price is down -12.26% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 392,308 shares of the stock traded hands, down from an average trading volume of 953,365

See Chart Below


Tesaro has a 52 week low of $106.64 and a 52 week high of $192.94 The company’s market cap is currently $0.

Also covering Tesaro's price target, a total of 10 analysts have released a research note on TSRO. The one year target is $89.00 with eight equity analysts rating the company a strong buy, four brokerages rating the company a buy, zero firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Tesaro (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.